Navigation Links
PDL BioPharma Elects Barry Selick to Its Board of Directors
Date:8/3/2009

INCLINE VILLAGE, Nev., Aug. 3 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced the appointment of Harold E. ("Barry") Selick, Ph.D., to the Company's Board of Directors.

"Barry's experience as a seasoned biotechnology executive and his extensive knowledge of PDL's humanization technology will allow him to make valuable contributions to our strategy and operations as we seek to maximize the value of our antibody humanization patents and related assets and monetize these assets for our stockholders," said John McLaughlin, president and chief executive officer of PDL.

Dr. Selick has served as chief executive officer of Threshold Pharmaceuticals since June 2002. From January 1999 to April 2002, he was chief executive officer of biotechnology company Camitro Corporation. From 1992 to 1999, he worked at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as vice president of Research. Prior to joining Affymax, he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he was a co-inventor of the technology underlying the creation of fully humanized antibody therapeutics and applied this technology to PDL's first product, Zenapax (R), which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
2. PDL BioPharma Announces Second Quarter 2009 Financial Results
3. PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009
4. DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller
5. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
6. Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
7. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
8. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
9. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
10. PDL BioPharma Announces Record Date for October 1 Dividend Payment
11. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... ... Brand EXOUS Bodygear announced today a special sale price for the EX-701 Knee ... the price will be only $19.97. The EXOUS Bodygear 65cm exercise ball ... $19.97). , The special promotional prices are to help individuals get their products at ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... buildings (MOBs) and other outpatient facilities, and who are the most active developers? ... those questions, Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an ... 20, 2017, at 1:00 PM ET. A recording of the webinar will also be ... Series. , Home health and hospice companies are still popular targets for healthcare investors. ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... now have easier access to the robotic-assisted total-hip and partial-knee replacement surgeries ... Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started performing these ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  The leader in accelerated orthodontics, OrthoAccel ® ... Daher , Manal Ibrahim , Kenji Ojima ... be the featured microlecture presenters at the AcceleDent ® ... Orthodontists (AAO) Annual Session, April 21-25, 2017. Orthodontists and ... daily at 11:20 a.m. On the opening morning of ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
(Date:3/29/2017)... 29, 2017 Transparency Market ... provides an exhaustive study of the U.S. substance abuse ... companies are functional in this market at present, ... leading companies, such as GlaxoSmithKline Plc., Pfizer Inc., ... on various marketing strategies to increase their visibility, ...
Breaking Medicine Technology: